{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-26-000910","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2026-07-02T11:05:55+00:00","discovered_at":"2026-07-02T11:10:00.349741+00:00","generated_at":"2026-07-02T11:10:07.967998+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcturus signs $80M collaboration with Thermo Fisher for ARCT-032 CF program","bullets":["Thermo Fisher to provide up to $40M in clinical manufacturing services; Arcturus to spend up to $40M on CRO services via PPD.","Collaboration supports Phase 3 development and potential commercialization of ARCT-032 for cystic fibrosis.","Upon regulatory approval, Thermo Fisher receives exclusive commercial manufacturing rights for ARCT-032.","Agreement includes technical transfer, clinical trial materials, PPQ batches, and stability studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-26-000910","json":"https://secwatch.observer/filing/0001193805-26-000910.json","markdown":"https://secwatch.observer/filing/0001193805-26-000910.md","text":"https://secwatch.observer/filing/0001193805-26-000910.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380526000910/0001193805-26-000910-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380526000910/e665618_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-02T11:10:07.967998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}